EGFR and congenital heart disease: Novel approaches, such as coating PTFE shunts with agents specifically suppressing pathways around EGF/EGFR and TIMP-1/MMP-9, might significantly reduce neointimal hyperplasia in SP shunts and therefore improve the outcome of children with complex and congenital heart defects.